Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) – Jefferies Group dropped their Q3 2017 earnings estimates for Spectrum Pharmaceuticals in a report released on Monday. Jefferies Group analyst M. Andrews now expects that the biotechnology company will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.16). Jefferies Group currently has a “Buy” rating and a $18.00 target price on the stock. Jefferies Group also issued estimates for Spectrum Pharmaceuticals’ Q4 2017 earnings at ($0.22) EPS, FY2017 earnings at ($0.96) EPS, FY2018 earnings at ($0.76) EPS, FY2020 earnings at $0.28 EPS and FY2021 earnings at $1.16 EPS.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.01. Spectrum Pharmaceuticals had a negative net margin of 59.33% and a negative return on equity of 30.95%. The company had revenue of $34.30 million during the quarter, compared to the consensus estimate of $30.50 million. During the same quarter in the prior year, the company posted ($0.35) EPS. The company’s quarterly revenue was up 1.0% compared to the same quarter last year.

WARNING: “Jefferies Group Weighs in on Spectrum Pharmaceuticals, Inc.’s Q3 2017 Earnings (SPPI)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/11/jefferies-group-weighs-in-on-spectrum-pharmaceuticals-inc-s-q3-2017-earnings-sppi.html.

A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. HC Wainwright raised their price objective on Spectrum Pharmaceuticals from $14.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. ValuEngine upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Finally, BidaskClub lowered Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $14.75.

Spectrum Pharmaceuticals (NASDAQ SPPI) opened at 14.05 on Wednesday. The firm’s market cap is $1.10 billion. The stock’s 50 day moving average is $11.03 and its 200-day moving average is $8.09. Spectrum Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $15.32.

Institutional investors and hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue raised its stake in shares of Spectrum Pharmaceuticals by 77.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 13,918 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 6,058 shares in the last quarter. Mason Street Advisors LLC raised its stake in shares of Spectrum Pharmaceuticals by 8.4% during the 1st quarter. Mason Street Advisors LLC now owns 16,577 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 1,279 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new stake in shares of Spectrum Pharmaceuticals during the 2nd quarter worth about $114,000. Municipal Employees Retirement System of Michigan raised its stake in shares of Spectrum Pharmaceuticals by 5.6% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 16,720 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 880 shares in the last quarter. Finally, Pillar Pacific Capital Management LLC purchased a new stake in shares of Spectrum Pharmaceuticals during the 2nd quarter worth about $138,000. 66.09% of the stock is owned by institutional investors.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Earnings History and Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Stock Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.